← All trials
NCT05626855
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2023
- Primary completion
- Nov 1, 2026
- Completion date
- Jan 1, 2027
- First posted
- Nov 25, 2022
- Last posted
- Nov 25, 2022
- Enrollment
- 260
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Scholar Rock, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.